Review-State-Aware Comparison
Amazonian Guaraná vs Andrographis
An automated side-by-side view of two public profiles. It has not been individually curated as a clinical comparison and is excluded from search indexing. Scores and narratives are provisional unless a profile explicitly states human approval; no personal dosage or combination conclusion is provided.
This page cannot establish which ingredient is better, whether either is effective, or whether they can be combined safely. Editorial and quality-gate review approved this evidence record. Editorial and quality-gate review approved this evidence record.
Human-Reviewed Benefit Text
Amazonian Guaraná
Andrographis
Human-Reviewed Mechanism Text
Guaraná's primary bioactive methylxanthines—caffeine (2–5% dry weight), theobromine, and theophylline—competitively antagonize adenosine A1 and A2A receptors in the central nervous system, thereby blocking adenosine's inhibitory signaling, increasing synaptic dopamine and norepinephrine release, and enhancing alertness, reaction time, and sustained attention. Its proanthocyanidins, catechins, and epicatechins scavenge reactive oxygen species (ROS) through electron donation from multiple hydroxyl groups and simultaneously activate the Keap1-Nrf2-ARE signaling axis, promoting transcription of phase II antioxidant enzymes including superoxide dismutase (SOD), glutathione peroxidase (GPx), and heme oxygenase-1 (HO-1). Guaraná's tannins and saponins further modulate NF-κB-mediated inflammatory cascades, reducing pro-inflammatory cytokines such as TNF-α and IL-6, which contributes to its documented anti-inflammatory and anti-apoptotic effects in dermal fibroblasts (PMID 31343815). Additionally, caffeine-mediated phosphodiesterase inhibition elevates intracellular cyclic AMP (cAMP), stimulating lipolysis and thermogenesis in adipose tissue, underpinning guaraná's metabolic activation properties.
Andrographolide and related compounds inhibit NF-κB transcriptional activity with IC₅₀ values of 2-2.4 μg/mL, reducing production of TNF-α, IL-6, MIP-2, and nitric oxide in stimulated macrophages. The herb blocks JAK/STAT signaling by inhibiting STAT1/2/3 phosphorylation and PI3K pathways while inducing apoptosis through caspase-3 activation and BAX upregulation. Additional mechanisms include Nrf2/HO-1 antioxidant pathway activation and ROS reduction via PKC modulation.
Human-Reviewed Safety Text
A comprehensive safety review by Patrick et al. (2019, PMID 31539257) confirmed that guaraná seed is generally recognized as safe (GRAS) when consumed at standard dietary doses (typically 75–200 mg/day caffeine equivalent), with adverse effects primarily dose-dependent and consistent with excess caffeine intake—including insomnia, tachycardia, anxiety, and gastrointestinal distress. Guaraná's caffeine is a substrate and inhibitor of cytochrome P450 1A2 (CYP1A2), and concurrent use with CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) or substrates (e.g., theophylline, clozapine) may increase plasma caffeine levels and potentiate adverse effects. Guaraná should be used cautiously alongside anticoagulants (warfarin), MAO inhibitors, stimulant medications, and ephedra-containing products due to additive cardiovascular stimulation; it is contraindicated in individuals with uncontrolled hypertension, cardiac arrhythmias, or caffeine hypersensitivity. Pregnant and lactating women are advised to limit guaraná consumption consistent with general caffeine guidelines (≤200 mg caffeine/day per WHO recommendations).
Current research lacks comprehensive safety data, drug interaction profiles, and specific contraindications for andrographis supplementation. The bitter taste may cause gastrointestinal discomfort in sensitive individuals, and the herb's immunomodulatory effects could theoretically interact with immunosuppressive medications. Pregnant and breastfeeding women should avoid use due to insufficient safety data and potential uterine stimulant properties. Patients on anticoagulant medications should exercise caution as andrographis may affect bleeding time, though specific interaction studies are not well-documented.
Comparison summary
This automated view does not establish that either Amazonian Guaraná or Andrographis is effective, superior, suitable, or safe to combine. Both have the same provisional public score (10/10). This ordering does not establish clinical superiority, safety, or suitability. Use the linked profiles and a qualified healthcare professional for decisions.
Frequently Asked Questions
Is Amazonian Guaraná or Andrographis better?
Amazonian Guaraná and Andrographis have the same provisional public score (10/10). A score tie does not establish equivalent evidence or outcomes.
Can you take Amazonian Guaraná and Andrographis together?
No reviewed combination conclusion is established by this comparison. A missing reviewed interaction record means unknown, not safe. Consult a qualified healthcare professional before combining supplements.
What is the main difference between Amazonian Guaraná and Andrographis?
Amazonian Guaraná is categorized as seed (Compound), while Andrographis is categorized as herb (botanical). Category labels are classification fields, not evidence of benefit; claim-bearing text appears only when both profiles have recorded human approval.
These statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.